CoChat
Sign Up
Cited by 122Diabetes Management and ResearchDiabetes Management and EducationDiabetes and associated disorders

A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems

Open access
Peacock, Sofia, Frizelle, Isolda, Hussain, Sufyan·2023·Diabetes Therapy
DOI 10.1007/s13300-023-01394-5PMC PMC10126177
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Several different forms of automated insulin delivery systems (AID systems) have recently been developed and are now licensed for type 1 diabetes (T1D). We undertook a systematic review of reported trials and real-world studies for commercial hybrid closed-loop (HCL) systems. METHODS: Pivotal, phase III and real-world studies using commercial HCL systems that are currently approved for use in type 1 diabetes were reviewed with a devised protocol using the Medline database. RESULTS: Fifty-nine studies were included in the systematic review (19 for 670G; 8 for 780G; 11 for Control-IQ; 14 for CamAPS FX; 4 for Diabeloop; and 3 for Omnipod 5). Twenty were real-world studies, and 39 were trials or sub-analyses. Twenty-three studies, including 17 additional studies, related to psychosocial outcomes and were analysed separately. CONCLUSIONS: These studies highlighted that HCL systems improve time In range (TIR) and arouse minimal concerns around severe hypoglycaemia. HCL systems are an effective and safe option for improving diabetes care. Real-world comparisons between systems and their effects on psychological outcomes require further study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01394-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Automated insulin delivery systems enhance glycemic control and mitigate hypoglycemia risk in individuals with type 1 diabetes.

    “Evidence from randomized controlled trials and real-world observational studies has demonstrated that these advanced systems enhance glycemic control, mitigate the risk of hypoglycemia, and improve the quality of life in individuals with type 1 diabetes, including adults, adolescents, and pediatric populations.2”

    From Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist (2026) · cites this paper as [2]

    The Introduction (page unavailable) reports improved glycaemic measures with commercial hybrid closed-loop systems. It says trials found no increase in hypoglycaemia and that some studies found a reduction; the Conclusions (page unavailable) likewise report no increase in severe hypoglycaemia. Thus the review supports improved glycaemic control, but not a general reduction in hypoglycaemia risk across these systems. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 85

  1. [1]Ramli R Reddy M Oliver N Artificial pancreas: current progress and future outlook in the treatment of type 1 diabetes Drugs 2019 79 1089 1101 10.1007/s40265-019-01149-2 31190305 · DOI
  2. [2]Castle JR DeVries JH Kovatchev B Future of automated insulin delivery systems Diabetes Technol Ther 2017 19 S67 S72 10.1089/dia.2017.0012 28585877 PMC5467099 · DOI
  3. [3]Jennings P Hussain S Do-it-yourself artificial pancreas systems: a review of the emerging evidence and insights for healthcare professionals J Diabetes Sci Technol 2019 10.1177/1932296819894296 31847570 PMC7753866 · DOI
  4. [5]Kesavadev J Saboo B Krishna MB Krishnan G Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas Diabetes Ther 2020 11 1251 1269 10.1007/s13300-020-00831-z 32410184 PMC7261311 · DOI · Paper page
  5. [6]Weisman A Bai JW Cardinez M Kramer CK Perkins BA Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials Lancet Diabetes Endocrinol 2017 5 501 512 10.1016/S2213-8587(17)30167-5 28533136 · DOI · Paper page
  6. [7]Bekiari E Kitsios K Thabit H Tauschmann M Athanasiadou E Karagiannis T Haidich AB Hovorka R Tsapas A Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis BMJ (Online) 2018 10.1136/bmj.k1310 29669716 PMC5902803 · DOI · Paper page
  7. [9]Tauschmann M, Allen JM, Wilinska ME, Thabit H, Stewart Z, Cheng P, Kollman C, Acerini CL, Dunger DB, Hovorka R. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2016;39:1168–74. PMC4915556 26740634
  8. [10]Thabit H Tauschmann M Allen JM Home use of an artificial beta cell in type 1 diabetes N Engl J Med 2015 10.1056/nejmoa1509351 26379095 PMC4697362 · DOI · Paper page
  9. [11]Saunders A Messer LH Forlenza GP MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy Exp Rev Med Dev 2019 16 845 853 10.1080/17434440.2019.1670639 PMC6816287 31540557 · DOI
  10. [12]Lal RA Maikawa CL Lewis D Full closed loop open-source algorithm performance comparison in pigs with diabetes Clin Transl Med 2021 10.1002/ctm2.387 33931977 PMC8087942 · DOI
  11. [13]Alexander CM Amiel S Beck R Need for regulatory change to incorporate beyond A1C glycemic metrics Diabetes Care 2018 10.2337/dci18-0010 29784704 · DOI
  12. [15]Gabbay MAL Rodacki M Calliari LE Time in range: a new parameter to evaluate blood glucose control in patients with diabetes Diabetol Metab Syndr 2020 10.1186/s13098-020-00529-z 32190124 PMC7076978 · DOI
  13. [16]Braune K Lal RA Petruželková L Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals Lancet Diabetes Endocrinol 2022 10.1016/S2213-8587(21)00267-9 34785000 PMC8720075 · DOI · Paper page
  14. [17]Burnside MJ Lewis DM Crocket HR Open-source automated insulin delivery in type 1 diabetes N Engl J Med 2022 387 869 881 10.1056/NEJMoa2203913 36069869 · DOI · Paper page
  15. [18]Knoll C Peacock S Wäldchen M Cooper D Aulakh SK Raile K Hussain S Braune K Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: a systematic review Diabet Med 2022 10.1111/dme.14741 34773301 · DOI
  16. [20]Schliess F Heise T Benesch C Artificial pancreas systems for people with type 2 diabetes: conception and design of the European CLOSE Project J Diabetes Sci Technol 2019 10.1177/1932296818803588 30241444 PMC6399797 · DOI
  17. [21]Marshall DC Holloway M Korer M Woodman J Brackenridge A Hussain S Do-it-yourself artificial pancreas systems in type 1 diabetes: perspectives of two adult users, a caregiver and three physicians Diabetes Ther 2019 10.1007/s13300-019-00679-y 31440989 PMC6778569 · DOI
  18. [22]Sherwood JS Russell SJ Putman MS New and emerging technologies in type 1 diabetes Endocrinol Metab Clin N Am 2020 49 667 678 10.1016/j.ecl.2020.07.006 PMC7556222 33153673 · DOI
  19. [24]Forlenza GP Buckingham BA Brown SA First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes Diabetes Technol Ther 2021 10.1089/dia.2020.0546 33325779 PMC8215410 · DOI
  20. [25]Benhamou PY Huneker E Franc S Doron M Charpentier G Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study Acta Diabetol 2018 10.1007/s00592-018-1123-1 29520615 · DOI
  21. [27]Quemerais MA Doron M Dutrech F Preliminary evaluation of a new semi-closed-loop insulin therapy system over the prandial period in adult patients with type 1 diabetes: the WP6.0 diabeloop study J Diabetes Sci Technol 2014 10.1177/1932296814545668 25097057 PMC4455472 · DOI
  22. [28]Boughton CK Hovorka R New closed-loop insulin systems Diabetologia 2021 10.1007/s00125-021-05391-w 33550442 PMC8012332 · DOI
  23. [29]Benhamou PY Lablanche S Vambergue A Doron M Franc S Charpentier G Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: a series of N-of-1 randomized controlled trials Diabetes Obes Metab 2021 10.1111/dom.14214 33001536 · DOI
  24. [30]Tubiana-Rufi N Schaepelynck P Franc S Practical implementation of automated closed-loop insulin delivery: a French position statement Diabetes Metab 2020 10.1016/j.diabet.2020.10.004 33152550 · DOI
  25. [31]Cobry EC Berget C Messer LH Forlenza GP Review of the Omnipod®5 automated glucose control system powered by Horizon™ for the treatment of type 1 diabetes Ther Deliv 2020 10.4155/tde-2020-0055 32723002 PMC8097502 · DOI
  26. [33]Amadou C, Franc S, Benhamou P-Y, Lablanche S, Huneker E, Charpentier G, Penfornis A. Diabeloop DBLG1 closed-loop system enables patients with type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events: 6-month follow-up. Diabetes Care. 2021;44:844–6. 33431420
  27. [35]Petrovski G al Khalaf F Campbell J Umer F Almajaly D Hamdan M Hussain K One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes Acta Diabetol 2020 10.1007/s00592-020-01607-4 33044604 PMC7548407 · DOI
  28. [36]Salehi P Roberts AJ Kim GJ Efficacy and safety of real-life usage of MiniMed 670G automode in children with type 1 diabetes less than 7 years old Diabetes Technol Ther 2019 10.1089/dia.2019.0123 31166801 · DOI
  29. [37]Stone MP Agrawal P Chen X Liu M Shin J Cordero TL Kaufman FR Retrospective analysis of 3-month real-world glucose data after the minimed 670G system commercial launch Diabetes Technol Ther 2018 10.1089/dia.2018.0202 30160523 · DOI
  30. [38]Beato-Víbora PI Gallego-Gamero F Lázaro-Martín L del Romero-Pérez M Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: a focus on superiority over predictive low-glucose suspend technology Diabetes Technol Ther 2020 10.1089/dia.2019.0400 31855446 · DOI
  31. [39]Akturk HK Giordano D Champakanath A Brackett S Garg S Snell-Bergeon J Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes Diabetes Obes Metab 2020 10.1111/dom.13933 31789447 · DOI
  32. [40]Usoh CO Johnson CP Speiser JL Bundy R Dharod A Aloi JA Real-world efficacy of the hybrid closed-loop system J Diabetes Sci Technol 2021 10.1177/1932296820985103 33430621 PMC9294561 · DOI
  33. [41]Lal RA Basina M Maahs DM Hood K Buckingham B Wilson DM One year clinical experience of the first commercial hybrid closed-loop system Diabetes Care 2019 10.2337/dc19-0855 31548247 PMC6868462 · DOI · Paper page
  34. [42]Lepore G Scaranna C Corsi A Dodesini AR Trevisan R Switching from suspend-before-low insulin pump technology to a hybrid closed-loop system improves glucose control and reduces glucose variability: a retrospective observational case-control study Diabetes Technol Ther 2020 10.1089/dia.2019.0302 31617752 · DOI
  35. [43]Faulds ER Zappe J Dungan KM Real-world implications of hybrid close loop (HCl) insulin delivery system Endocr Pract 2019 10.4158/EP-2018-0515 30865545 PMC6832708 · DOI
  36. [44]Berget C Messer LH Vigers T Frohnert BI Pyle L Wadwa RP Driscoll KA Forlenza GP Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system Pediatr Diabetes 2020 10.1111/pedi.12962 31837064 PMC7204168 · DOI
  37. [45]Duffus SH al Ta’ani Z Slaughter JC Niswender KD Gregory JM Increased proportion of time in hybrid closed-loop “auto mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump Diabetes Obes Metab 2020 10.1111/dom.13912 31709736 PMC7549138 · DOI
  38. [46]Petrovski G, al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. 10-day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol. 2020. 10.1007/s00592-019-01472-w. PMC7220973 31953687 · DOI
  39. [47]Hsu L Buckingham B Basina M Ekhlaspour L von Eyben R Wang J Lal RA Fast-acting insulin aspart use with the MiniMedTM670G system Diabetes Technol Ther 2021 10.1089/dia.2020.0083 32520594 PMC7864093 · DOI
  40. [48]Forlenza GP Pinhas-Hamiel O Liljenquist DR Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes Diabetes Technol Ther 2019 10.1089/dia.2018.0264 30585770 PMC6350071 · DOI
  41. [50]Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the Mini Med 670G system. Diabetes Care. 2018. 10.2337/dc17-1682. PMC6463622 29444895 · DOI
  42. [51]McAuley SA Lee MH Paldus B Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized controlled trial Diabetes Care 2020 10.2337/dc20-1447 33055139 · DOI · Paper page
  43. [53]Forlenza GP Ekhlaspour L DiMeglio LA Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial Pediatr Diabetes 2022 10.1111/pedi.13312 35001477 PMC9304187 · DOI
  44. [55]Pintaudi B Gironi I Nicosia R Meneghini E Disoteo O Mion E Bertuzzi F Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus Nutr Metab Cardiovasc Dis 2022 32 1719 1724 10.1016/j.numecd.2022.03.031 35599092 · DOI
  45. [56]Beato-Víbora PI Gallego-Gamero F Ambrojo-López A Gil-Poch E Martín-Romo I Arroyo-Díez FJ Amelioration of user experiences and glycaemic outcomes with an advanced hybrid closed loop system in a real-world clinical setting Diabetes Res Clin Pract 2021 10.1016/j.diabres.2021.108986 34329691 · DOI
  46. [57]Schiaffini R Deodati A Nicoletti MC Comparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational study Acta Diabetol 2022 59 959 964 10.1007/s00592-022-01886-z 35451679 · DOI
  47. [58]Thivolet C Gaudilliere M Villar Fimbel S Bendelac N Mestre B Protsenko N Brunot S Nicolino M Hybrid closed loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring Acta Diabetol 2022 59 395 401 10.1007/s00592-021-01820-9 34725723 PMC8559915 · DOI
  48. [62]Kanapka LG Wadwa RP Breton MD Extended use of the control-IQ closed-loop control system in children with type 1 diabetes Diabetes Care 2021 10.2337/dc20-1729 33355258 PMC7818334 · DOI
  49. [63]O’Malley G Messer LH Levy C Clinical management and pump parameter adjustment of the control-IQ closed-loop control system: results from a 6-month multicenter randomized clinical trial Diabetes Technol Ther 2020 10.1089/dia.2020.0472 33155824 PMC8114941 · DOI
  50. [64]Brown SA, Beck RW, Raghinaru D, et al. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2020;43:1822–8. PMC7372060 32471910
  51. [65]Isganaitis E Raghinaru D Ambler-Osborn L Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the International Diabetes Closed-Loop Trial Diabetes Technol Ther 2021 10.1089/dia.2020.0572 33216667 PMC8080922 · DOI · Paper page
  52. [66]Bisio A Brown SA McFadden R Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents Pediatr Diabetes 2020 10.1111/pedi.13164 33289242 · DOI
  53. [67]Bisio A Gonder-Frederick L McFadden R Cherñavvsky D Voelmle M Pajewski M Yu P Bonner H Brown SA The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: a pilot study J Diabetes Sci Technol 2021 10.1177/1932296820986879 33451264 PMC9294584 · DOI
  54. [69]Akturk HK Snell-Bergeon J Shah VN Efficacy and safety of tandem control IQ without user-initiated boluses in adults with uncontrolled type 1 diabetes Diabetes Technol Ther 2022 24 779 783 10.1089/dia.2022.0162 35714344 · DOI
  55. [70]Renard E Tubiana-Rufi N Bonnemaison E Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: a multicentre, randomized clinical trial Diabetes Obes Metab 2022 24 511 521 10.1111/dom.14605 34816597 · DOI
  56. [71]Ekhlaspour L, Raghinaru D, Forlenza GP, et al. Outcomes in pump- and CGM-baseline use subgroups in the International Diabetes Closed-Loop (iDCL) Trial. J Diabetes Sci Technol. 2022:193229682210893. PMC10347978 35473359
  57. [72]Boughton CK Hartnell S Thabit H Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study Diabetes Obes Metab 2021 10.1111/dom.14355 33606901 PMC11497277 · DOI
  58. [73]Tauschmann M Allen JM Nagl K Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multicenter, 3-week, randomized trial Diabetes Care 2019 10.2337/dc18-1881 30692242 · DOI
  59. [74]Ruan Y Bally L Thabit H Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes Diabetes Obes Metab 2018 10.1111/dom.13304 29577536 PMC6043360 · DOI
  60. [75]Bally L Thabit H Ruan Y Bolusing frequency and amount impacts glucose control during hybrid closed-loop Diabet Med 2018 10.1111/dme.13436 28755444 PMC5788742 · DOI
  61. [77]Tauschmann M Allen JM Wilinska ME Thabit H Acerini CL Dunger DB Hovorka R Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial Diabetes Care 2016 10.2337/dc16-1094 27612500 PMC5079605 · DOI
  62. [78]Bally L Thabit H Kojzar H Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study Lancet Diabetes Endocrinol 2017 10.1016/S2213-8587(17)30001-3 28094136 PMC5379244 · DOI
  63. [79]Thabit H Lubina-Solomon A Stadler M Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study Lancet Diabetes Endocrinol 2014 10.1016/S2213-8587(14)70114-7 24943065 PMC4165604 · DOI
  64. [81]Stewart ZA Wilinska ME Hartnell S Closed-loop insulin delivery during pregnancy in women with type 1 diabetes N Engl J Med 2016 10.1056/nejmoa1602494 27532830 · DOI · Paper page
  65. [82]Ware J Boughton CK Allen JM Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial Lancet Digit Health 2022 4 e245 e255 10.1016/S2589-7500(22)00020-6 35272971 · DOI
  66. [83]Ng SM Katkat N Day H Hubbard R Quinn M Finnigan L Real-world prospective observational single-centre study: hybrid closed loop improves HbA1c, time-in-range and quality of life for children, young people and their carers Diabet Med 2022 10.1111/dme.14863 35488481 · DOI
  67. [85]Kariyawasam D Morin C Casteels K Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial Lancet Digit Health 2022 4 e158 e168 10.1016/S2589-7500(21)00271-5 35216750 · DOI
  68. [86]Brown RE Vienneau T Aronson R Canadian real-world outcomes of omnipod initiation in people with type 1 diabetes (COPPER study): evidence from the LMC Diabetes Registry Diabet Med 2021 10.1111/dme.14420 33040383 PMC8246772 · DOI
  69. [87]Sherr JL Bode BW Forlenza GP Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial Diabetes Care 2022 45 1907 1910 10.2337/dc21-2359 35678724 PMC9346983 · DOI
  70. [88]Messer LH Berget C Vigers T Pyle L Geno C Wadwa RP Driscoll KA Forlenza GP Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months Pediatr Diabetes 2020 10.1111/pedi.12971 31885123 PMC7204392 · DOI
  71. [89]Grando MA Bayuk M Karway G Corrette K Groat D Cook CB Thompson B Patient perception and satisfaction with insulin pump system: pilot user experience survey J Diabetes Sci Technol 2019 10.1177/1932296819843146 31055947 PMC6835185 · DOI
  72. [90]Cobry EC Hamburger E Jaser SS Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents Diabetes Technol Ther 2020 10.1089/dia.2020.0057 32212971 PMC7698988 · DOI
  73. [91]Cobry EC Kanapka LG Cengiz E Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control Diabetes Technol Ther 2021 10.1089/dia.2020.0532 33404325 PMC8215424 · DOI
  74. [92]Musolino G Dovc K Boughton CK Reduced burden of diabetes and improved quality of life: experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes Pediatr Diabetes 2019 10.1111/pedi.12872 31140654 PMC6771658 · DOI
  75. [93]Lawton J Blackburn M Rankin D Participants’ experiences of, and views about, daytime use of a day-and-night hybrid closed-loop system in real life settings: longitudinal qualitative study Diabetes Technol Ther 2019 10.1089/dia.2018.0306 30720338 PMC6434584 · DOI
  76. [94]Barnard KD Wysocki T Ully V Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy J Diabetes Sci Technol 2017 10.1177/1932296817702656 28367636 PMC5951034 · DOI
  77. [95]Barnard KD Wysocki T Thabit H Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with type 1 diabetes in the home setting Diabet Med 2015 10.1111/dme.12706 25615888 · DOI
  78. [96]Abraham MB de Bock M Smith GJ Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes JAMA Pediatr 2021 175 1227 10.1001/jamapediatrics.2021.3965 34633418 PMC8506294 · DOI
  79. [97]Kudva YC Laffel LM Brown SA Patient-reported outcomes in a randomized trial of closed-loop control: the pivotal International Diabetes Closed-Loop Trial Diabetes Technol Ther 2021 10.1089/dia.2021.0089 34115959 PMC8573794 · DOI
  80. [98]Gianini A Suklan J Skela-Savič B Klemencic S Battelino T Dovc K Bratina N Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery Front Endocrinol (Lausanne) 2022 10.3389/fendo.2022.967725 36060958 PMC9437950 · DOI
  81. [99]Petrovski G al Khalaf F Campbell J Day E Almajaly D Hussain K Pasha M Umer F Hamdan M Khalifa A Glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections (MiniMed 780G system in T1D individuals, previously treated with MDI) BMC Endocr Disord 2022 10.1186/s12902-022-00996-7 35351095 PMC8962027 · DOI
  82. [100]Hood KK Garcia-Willingham N Hanes S Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents Diabetes Obes Metab 2022 24 2309 2318 10.1111/dom.14815 35837984 PMC9804666 · DOI
  83. [101]de Beaufort C Schierloh U Thankamony A Cambridge hybrid closed-loop system in very young children with type 1 diabetes reduces caregivers’ fear of hypoglycemia and improves their well-being Diabetes Care 2022 45 3050 3053 10.2337/dc22-0693 36350787 PMC9862472 · DOI
  84. [102]Vigersky RA McMahon C The relationship of hemoglobin A1C to time-in-range in patients with diabetes Diabetes Technol Ther 2019 10.1089/dia.2018.0310 30575414 · DOI · Paper page
  85. [103]The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 977 986 10.1056/NEJM199309303291401 8366922 · DOI · Paper page

Cited by

Sorted by citations

Authors
Peacock, S., Frizelle, I., & Hussain, S.
Affiliations
St Thomas' Hospital (GB)
Corresponding author
Hussain, Sufyan
ORCID
Venue
Diabetes Therapy
Publisher
Springer Science and Business Media LLC
Published
2023-04-05
Volume
14
Issue
5
Pages
839-855
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
DOI
10.1007/s13300-023-01394-5
PMC
PMC10126177
OpenAlex
W4362601771
Cited by
122
References
17
Citations by year
2026: 37 · 2025: 49 · 2024: 32 · 2023: 4
FWCI
4.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Medical Research Council (MR/W030004/1)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
hybrid closed-loop system, artificial pancreas, type 1 diabetes, time in range, hypoglycemia, psychosocial outcomes, real-world evidence, Control-IQ, CamAPS FX, Omnipod 5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review